Physician profile
Albert E Smolyar
NPI 1194777185
$2,262.62
in general payments reported to CMS, 2019-2025
21 companies · $166 in 2025
The $166 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $605 · 2020: $337 · 2021: $353 · 2022: $288 · 2023: $308 · 2024: $205 · 2025: $166.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $679.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $678.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $731.38 | 2019-2025 | Clareon Panoptix Pro, Rocklatan, Clareon |
| Dompe US, INC. | $215.38 | 2019-2025 | Oxervate |
| Kala Pharmaceuticals, INC. | $204.71 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $203.68 | 2019-2023 | Cequa |
| Bausch & Lomb Americas INC. | $158.48 | 2022-2024 | Stellaris, Miebo, Xiidra |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $87.79 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $87.44 | 2021-2023 | Acthar |
| Abbvie INC. | $85.06 | 2022-2023 | Durysta |
| Allergan, INC. | $79.17 | 2021-2022 | |
| Ocular Therapeutix, INC. | $73.87 | 2019-2024 | Dextenza |
| Novartis Pharmaceuticals Corporation | $65.29 | 2019-2023 | |
| Thea Pharma INC. | $46.45 | 2022-2023 | Iyuzeh |
| Beaver-Visitec International, INC. | $42.33 | 2021 | |
| Aerie Pharmaceuticals, INC. | $40.75 | 2020-2021 | |
| Tarsus Pharmaceuticals, INC. | $24.79 | 2024 | Xdemvy |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Recordati_rare_diseases_inc. | $24.47 | 2021 | |
| Glaukos Corporation | $24.09 | 2024 | Ce-Marked Kxla System |
| Eyevance Pharmaceuticals LLC | $18.53 | 2020 | |
| Harrow Eye, LLC | $17.02 | 2024 | Vevye |
| Sight Sciences, INC. | $16.16 | 2021 | |
| Horizon Therapeutics Plc | $15.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Albert Smolyar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.